Group 1 - The core viewpoint of the articles highlights the significant growth potential in the global GLP-1 drug market, primarily dominated by Novo Nordisk and Eli Lilly, with other multinational corporations (MNCs) accelerating their presence in this sector [1][2] - The stock price of Paig BioPharma-B (02565) has increased over 3.1 times since its listing, with a current rise of 5.25% to HKD 54.15, and a trading volume of HKD 19.87 million [1] - Zhejiang Securities emphasizes that the GLP-1 market has substantial room for growth in terms of patient base and market size, making it a critical area for MNCs in the metabolic disease sector [1] Group 2 - PB-718, a key product of Paig BioPharma, is a novel long-acting GLP-1/GCG dual receptor agonist targeting MASH treatment, showing promising clinical progress [2] - The Phase Ib/IIa clinical trial results for PB-718 indicate a significant reduction in liver fat content, with a mean percentage change of -57.14% after 18 weeks at a dosage of 1.6mg, achieving a maximum reduction of 62%, outperforming semaglutide in a shorter treatment duration [2] - The domestic pipeline in the multi-target GLP-1 field is advancing, with expectations for major business development (BD) events to emerge [2]
派格生物医药-B午前涨超5% GLP-1多靶点领域临床进度靠前 PB-718为公司旗下重磅品种